Drugs / CU-20401
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05173883 | Dec 2021 → Nov 2023 | — | Cutia Therapeutics (Wuxi) Co., Ltd | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05195541 | Feb → Dec 2022 | — | Cutia Therapeutics (Wuxi) Co., Ltd | Completed | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT06194188 | Dec 2023 → Sep 2024 | — | Cutia Therapeutics (Wuxi) Co., Ltd | Completed | Met primary |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2024-12-30 | Cutia Therapeutics（Wuxi）Co.,Ltd | Results VOLUNTARY ANNOUNCEMENT - COMPLETION OF PHASE II CLINICAL TRIAL OF CU-20401
(RECOMBINANT MUTANT COLLAGENASE) FOR
SUBMENTAL ADIPOSE ACCUMULATION IN CHINA cutiatx.com ↗
The Clinical Trial has demonstrated significant and robust efficacy advantages with favorable safety profile. |
| 2024-12-30 | Cutia Therapeutics（Wuxi）Co.,Ltd | Results 自願公告 - CU-20401（重組突變膠原酶）治療頦下脂肪堆積完成中國II期臨床試驗 cutiatx.com ↗ |
| 2024-11-28 | Cutia Therapeutics（Wuxi）Co.,Ltd | Results VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF CU-20401 (RECOMBINANT MUTANT
COLLAGENASE) FOR SUBMENTAL ADIPOSE ACCUMULATION REACHED PRIMARY ENDPOINT cutiatx.com ↗
The board of directors (the “Board”) of the Company is pleased to announce that the Phase II clinical trial (the “Clinical Trial ”) of CU-20401 (recombinant mutant collagenase), a potential Class I new drug of the Group, for the treatment of submental adipose accumulation in China, has obtained top-line results. |
| 2024-11-28 | Cutia Therapeutics（Wuxi）Co.,Ltd | Results 自願公告 - CU-20401（重組突變膠原酶）治療頦下脂肪堆積II期臨床試驗達到主要終點 cutiatx.com ↗ |
| 2024-02-27 | Cutia Therapeutics（Wuxi）Co.,Ltd | Results VOLUNTARY ANNOUNCEMENT - COMPLETION OF PHASE I CLINICAL TRIAL OF CU-20401
(RECOMBINANT MUTANT COLLAGENASE) FOR
ABDOMINAL ADIPOSE ACCUMULATION IN CHINA cutiatx.com ↗
Data from the clinical trial demonstrated an overall favorable safety and tolerability profile for CU-20401, with no significant dose-related effects. |
| 2024-02-27 | Cutia Therapeutics（Wuxi）Co.,Ltd | Results 自愿公告 - CU-20401（重组突变胶原酶）治疗腹部脂肪堆积完成中国I期临床试验 cutiatx.com ↗ |
All press releases naming this drug 18 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CU-20401 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06194188 ↗ |
| Route | Subcutaneous | “single subcutaneous injection of CU-20401” NCT05173883 ↗ |